

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Application No. 10/596,209	)	
		)	<i>Confirmation No. 3439</i>
Filed:	June 2, 2006	)	
		)	
Applicants:	Nanping ZHONG et al.	)	
		)	
Title:	METHOD FOR THE	)	
	ENANTIOMERIC SEPARATION	)	
	OF OPTICAL ACTIVE	)	
	AMLODIPINE	)	
		)	
Art Unit:	1625	)	
		)	
Examiner:	Not yet assigned	)	
		)	
		)	
Attorney Docket:	8378/88501	)	
		)	
Customer No.:	22242	)	

This Request For Corrected Filing Receipt  
was electronically filed on August 1, 2007  
using the USPTO's EFS-Web.

Commissioner for Patents  
P. O. Box 1450  
Alexandria, Virginia 22313-1450

ATTENTION: Office of Initial Patent Examination  
Filing Receipt Corrections

**REQUEST FOR CORRECTED FILING RECEIPT**

Sir:

Enclosed is a copy of the official Filing Receipt we received from the United States Patent and Trademark Office in connection with the above-identified application. The following errors of a typographical nature are noted thereon for which we respectfully request correction.

Under the section for Applicants, the city of residence for second inventor Xianfeng Zhao is misspelled. Please change Shijiazhueng to "Shijiazhuang". Support for this request is found in the Declaration and on page 1 of the Application Data Sheet.

Application No. 10/596,209

REQUEST FOR CORRECTED FILING RECEIPT dated August 1, 2007

Official Filing Receipt mailed January 17, 2007

Also under the section for Applicants, the first name of the fourth inventor Yujie Chen is misspelled. Please change Yujle to "Yujie". Support for this request is found in the Declaration and on page 2 of the Application Data Sheet.

Under the section for Assignment For Published Patent Application, the Assignee's name is misspelled. Please change Shijiazhuang Pharmaceutical Group Ouyi Pharma Co., Ltd to "Shijiazhuang Pharmaceutical Group Oyui Pharma. Co., Ltd." Support for this request is found in the Assignment and on page 4 of the Application Data Sheet.

Copies of the Declaration, Assignment, and Application Data Sheet are attached hereto for convenience. It is respectfully requested that the United States Patent and Trademark Office issue a corrected Filing Receipt to incorporate all of the changes herein requested.

The Commissioner is hereby authorized to charge any additional fees which may be required with respect to this communication, or credit any overpayment, to Deposit Account No. 06-1135.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

Dated: August 1, 2007



Edward E. Clair

Registration No. 51,565

120 South LaSalle Street, Suite 1600  
Chicago, Illinois 60603-3406  
Telephone (312) 577-7000  
Facsimile (312) 577-7007  
488656

114



## UNITED STATES PATENT AND TRADEMARK OFFICE

EFC/ALC

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL. NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/596,209	06/02/2006	1625	900	8378/88501		12	2

CONFIRMATION NO. 3439

22242  
 FITCH EVEN TABIN AND FLANNERY  
 120 SOUTH LA SALLE STREET  
 SUITE 1600  
 CHICAGO, IL 60603-3406

## FILING RECEIPT



\*OC000000022000330\*

Date Mailed: 01/17/2007

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Nanping Zhong, Shijiazhuang, CHINA;  
 Xianfeng Zhao, Shijiazhuang, CHINA; Shijiazhuang  
 Hui Ma, Shijiazhuang, CHINA;  
 Yujie Yujie Chen, Shijiazhuang, CHINA;

22242  
 201

## Assignment For Published Patent Application

SHIJIAZHUANG PHARMACEUTICAL GROUP GUYL PHAMA CO., LTD, SHIJIAZHUANG,  
 CHINA

Guyi Pharma. Ltd.

Power of Attorney: The patent practitioners associated with Customer Number 22242.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/CN04/01412 12/03/2004

## Foreign Applications

CHINA 200310119335.7 12/05/2003

If Required, Foreign Filing License Granted: 01/16/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/596,209**

Projected Publication Date: 04/26/2007

Non-Publication Request: No

Early Publication Request: No

**Title**

Method for the enantiomeric separation of optical active amlodipine

**Preliminary Class**

546

## **PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES**

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

### **LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where

the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**DECLARATION  
FOR UTILITY OR DESIGN  
PATENT APPLICATION**

- ☒ Declaration Submitted With  
Initial Filing
- ☐ Declaration Submitted After  
Initial Filing

Attorney Docket No.: 8378/88501  
Customer No.: 22242

---

First Named Inventor: Nanping ZHONG et al.  
Application Number: Not yet assigned  
Filing Date: Herewith  
Art Unit: Not yet assigned  
Examiner Name: Not yet assigned

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**A METHOD FOR THE ENANTIOMERIC SEPARATION OF OPTICAL ACTIVE AMLODIPINE**

(Title of Invention)

the specification of which:

- ☒ Is attached hereto, or
- ☐ was filed by an authorized person on my behalf on \_\_\_\_\_ as United States Application Number \_\_\_\_\_ or PCT International Application Number \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below, and I have also identified below, by checking the box, any foreign

application for patent or inventor's certificate, or any PCT international application, on this invention filed by me or my legal representatives or assigns and having a filing date before that of the application on which priority is claimed:

<u>Prior Foreign Application Number(s)</u>	<u>Country</u>	<u>Foreign Filing Date</u>	<u>Priority Not Claimed</u>
200310119335.7	China	December 5, 2003	<input checked="" type="checkbox"/>

☒ Additional foreign application numbers are listed on a supplemental priority data sheet attached hereto.

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

<u>Provisional Application Number(s)</u>	<u>Provisional Application Filing Date</u>
NONE	

☒ Additional provisional application numbers are listed on a supplemental priority data sheet attached hereto.

I hereby claim the benefit under Title 35, United States Code, §120, of any prior United States application(s), or under §365(c) of any PCT international application(s) designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information known by me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56, which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

<u>Prior U.S. Application Number</u>	<u>Prior PCT International Application Number</u>	<u>Filing Date of U.S. or PCT International Application</u>	<u>Patent Number (if applicable)</u>
	PCT/CN2004/001412	December 3, 2004	

☒ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet attached hereto.

As a named inventor, I hereby appoint the practitioners associated with Customer Number 22242, with full power of substitution and revocation, to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, and request that all correspondence and telephone calls in respect to this application be directed to FITCH, EVEN, TABIN & FLANNERY, Suite 1600, 120 South LaSalle Street, Chicago, Illinois 60603-3406, Telephone No. (312) 577-7000, Facsimile No. (312) 577-7007, CUSTOMER NUMBER 22242.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made herein on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity or enforceability of the application or any patent issued thereon.

Full name of sole or one joint inventor: Nenping Zhong  
(Given names first, with Family name last)

Inventor's signature:

钟南平

Date:

2006年6月1日

Residence:  
(City and State for U.S. Residents;  
City and Country for others)

Shijiazhuang, Hebei Province,  
Peoples Republic of China

Post Office Address:

Zhong-shan West Road 278  
Shijiazhuang, Hebei Province, 050051  
Peoples Republic of China

Citizenship:

Peoples Republic of China



Full name of one joint inventor:  
(Given names first, with Family name last)

Xianfeng Zhao

Inventor's signature:

赵险峰

Date:

2006.6.1

Residence:  
(City and State for U.S. Residents;  
City and Country for others)

Shijiazhuang, Hebei Province,  
Peoples Republic of China

Post Office Address:

Zhong-chen West Road 276  
Shijiazhuang, Hebei Province, 050051  
Peoples Republic of China

Citizenship:

Peoples Republic of China

Full name of one joint inventor:  
(Given names first, with Family name last)

Hui Ma

Inventor's signature:



Date:

2006.6.1

Residence:  
(City and State for U.S. Residents;  
City and Country for others)

Shijiazhuang, Hebei Province,  
Peoples Republic of China

Post Office Address:

Zhong-shan West Road 278  
Shijiazhuang, Hebei Province, 050051  
Peoples Republic of China

Citizenship:

Peoples Republic of China

Full name of one joint inventor:  
(Given names first, with Family name last)

Yujie Chen

Inventor's signature:

Yujie Chen

Date:

2016. 6. 1.

Residence:  
(City and State for U.S. Residents;  
City and Country for others)

Shijiazhuang, Hebei Province,  
Peoples Republic of China

Post Office Address:

Zhongshan West Road 276  
Shijiazhuang, Hebei Province, 050051  
Peoples Republic of China

Citizenship:

Peoples Republic of China

ASSIGNMENT

We, NANPING ZHONG, of Zhong-shan West Road 276, Shijiazhuang, Hebei Province, 050051, Peoples Republic of China, XIANFENG ZHAO, of Zhong-shan West Road 276, Shijiazhuang, Hebei Province, 050051, Peoples Republic of China, HUI MA, of Zhong-shan West Road 276, Shijiazhuang, Hebei Province, 050051, Peoples Republic of China, and YUJIE CHEN, of Zhong-shan West Road 276, Shijiazhuang, Hebei Province, 050051, Peoples Republic of China, for good and valuable consideration, receipt of which is hereby acknowledged, have assigned and do hereby assign to SHIJIAZHANG PHARMACEUTICAL GROUP OUYI PHARMA Co., LTD., having its principal place of business at Zhong-shan West Road 276, Shijiazhuang, Hebei Province, 050051, Peoples Republic of China, its successors, assigns and legal representatives, the entire right, title and interest, in and to all subject matter invented by us and disclosed in the National Phase Application for Letters Patent of the United States based on International Application Number PCT/CN2004/001412 and entitled

A METHOD FOR THE ENANTIOMERIC  
SEPARATION OF OPTICAL ACTIVE AMLODIPINE

and in and to all Letters Patent and all Convention and Treaty rights of all kinds, including the right to claim priority from said application, and all rights in and to any continuation, continuation-in-part, and divisional application therefrom, and any reissue or re-examination as to any Letters Patent issuing therefrom, in all countries

throughout the world, for all such subject matter described therein, including all rights of action and rights to recover damages for past infringements. I agree to sign all documents necessary to secure all said Letters Patent and rights, and request issuance of all said Letters Patent to the above assignee in accordance with this assignment.

We hereby authorize and request our attorneys, Fitch, Even, Tabin & Flannery, of 120 South LaSalle Street, Suite 1600, Chicago, Illinois 60603-3406, to insert here in parenthesis (Application No. 10/596,209, filed June 2, 2006) the filing date and application number of said application when known.

6月1日, 2006

钟南平  
Nanping Zhong

6月1日, 2006

赵险峰  
Xianfeng Zhao

6月1日, 2006

马辉  
Hui Ma

6月1日, 2006

陈玉洁  
Yujie Chen

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


<b>Application Data Sheet 37 CFR 1.76</b>		<b>Attorney Docket Number</b>	8378/88501
		<b>Application Number</b>	
<b>Title of Invention</b>	A Method For The Enantiomeric Separation Of Optical Active Amlodipine		
<p>The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76. This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.</p>			

**Secrecy Order 37 CFR 5.2**



- ☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

**Applicant Information:**

<b>Applicant 1</b>			
<b>Applicant Authority</b> <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117	
		<input type="radio"/> Party of Interest under 35 U.S.C. 118	
<b>Prefix</b>	<b>Given Name</b>	<b>Middle Name</b>	<b>Family Name</b>
	Nanping		Zhong
<b>Residence Information (Select One)</b> <input type="radio"/> US Residency <input checked="" type="radio"/> Non US Residency <input type="radio"/> Active US Military Service			
<b>City</b>	Shijiazhuang	<b>Country Of Residence</b>	CN
<b>Citizenship under 37 CFR 1.41(b) i</b>		CN	
<b>Mailing Address of Applicant:</b>			
<b>Address 1</b>	Zhong-shan West Road 276		
<b>Address 2</b>			
<b>City</b>	Shijiazhuang, Hebei Province	<b>State/Province</b>	
<b>Postal Code</b>	050051	<b>Country</b>	China
<b>Applicant 2</b>			
<b>Applicant Authority</b> <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117	
		<input type="radio"/> Party of Interest under 35 U.S.C. 118	
<b>Prefix</b>	<b>Given Name</b>	<b>Middle Name</b>	<b>Family Name</b>
	Xianfeng		Zhao
<b>Residence Information (Select One)</b> <input type="radio"/> US Residency <input checked="" type="radio"/> Non US Residency <input type="radio"/> Active US Military Service			
<b>City</b>	Shijiazhuang	<b>Country Of Residence</b>	CN
<b>Citizenship under 37 CFR 1.41(b) i</b>		CN	
<b>Mailing Address of Applicant:</b>			
<b>Address 1</b>	Zhong-shan West Road 276		
<b>Address 2</b>			
<b>City</b>	Shijiazhuang, Hebei Province	<b>State/Province</b>	
<b>Postal Code</b>	050051	<b>Country</b>	China
<b>Applicant 3</b>			
<b>Applicant Authority</b> <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117	
		<input type="radio"/> Party of Interest under 35 U.S.C. 118	
<b>Prefix</b>	<b>Given Name</b>	<b>Middle Name</b>	<b>Family Name</b>
	Hui		Ma
<b>Residence Information (Select One)</b> <input type="radio"/> US Residency <input checked="" type="radio"/> Non US Residency <input type="radio"/> Active US Military Service			
<b>City</b>	Shijiazhuang	<b>Country Of Residence</b>	CN

<b>Application Data Sheet 37 CFR 1.76</b>		Attorney Docket Number	8378/88501	
		Application Number		
Title of Invention	A Method For The Enantiomeric Separation Of Optical Active Amlodipine			
Citizenship under 37 CFR 1.41(b) i		CN		
Mailing Address of Applicant:				
Address 1	Zhong-shan West Road 276			
Address 2				
City	Shijiazhuang, Hebei Province	State/Province		
Postal Code	050051	Country	China	
Applicant 4				
Applicant Authority <input checked="" type="radio"/> Inventor		<input type="radio"/> Legal Representative under 35 U.S.C. 117		<input type="radio"/> Party of Interest under 35 U.S.C. 118
Prefix	Given Name	Middle Name	Family Name	Suffix
	Yujie		Chen	
Residence Information (Select One) <input type="radio"/> US Residency <input checked="" type="radio"/> Non US Residency <input type="radio"/> Active US Military Service				
City	Shijiazhuang	Country Of Residence i	CN	
Citizenship under 37 CFR 1.41(b) i		CN		
Mailing Address of Applicant:				
Address 1	Zhong-shan West Road 276			
Address 2				
City	Shijiazhuang, Hebei Province	State/Province		
Postal Code	050051	Country	China	
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the Add button. <span style="float: right;"></span>				

### Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below. For further information see 37 CFR 1.33(a).	
<input type="checkbox"/> An Address is being provided for the correspondence information of this application.	
Customer Number	22242
Email Address	edclair@ftcheven.com <span style="float: right;"> </span>

### Application Information:

Title of the Invention	A Method For The Enantiomeric Separation Of Optical Active Amlodipine		
Attorney Docket Number	8378/88501	Small Entity Status Claimed	<input type="checkbox"/>
Application Type	Nonprovisional		
Subject Matter	Utility		
Suggested Class (if any)		Sub Class (if any)	
Suggested Technology Center (if any)			
Total Number of Drawing Sheets (If any)		Suggested Figure for Publication (if any)	

<b>Application Data Sheet 37 CFR 1.76</b>		Attorney Docket Number	8378/88501
		Application Number	
Title of Invention	A Method For The Enantioselective Separation Of Optical Active Amlodipine		

<b>Publication Information:</b>	
<input type="checkbox"/>	Request Early Publication (Fee required at time of Request 37 CFR 1.219)
<input type="checkbox"/>	Request Not to Publish. I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not been and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing.

### Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Enter either Customer Number or complete the Representative Name section below. If both sections are completed the Customer Number will be used for the Representative Information during processing.			
Please Select One:	<input checked="" type="radio"/> Customer Number	<input type="radio"/> US Patent Practitioner	<input type="radio"/> US Representative (37 CFR 11.9)
Customer Number	22242		

### Domestic Priority Information:

This section allows for the applicant to claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c). Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78(a)(2) or CFR 1.78(a)(4), and need not otherwise be made part of the specification.			
Prior Application Status		<a href="#">Remove</a>	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)
	a 371 of International	PCT/CN2004/001412	2004-12-03
Additional Domestic Priority Data may be generated within this form by selecting the Add button.			

### Foreign Priority Information:

This section allows for the applicant to claim benefit of foreign priority and to identify any prior foreign application for which priority is not claimed. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(a).			
<a href="#">Remove</a>			
Application Number	Country <sup>1</sup>	Parent Filing Date (YYYY-MM-DD)	Priority Claimed
200310119335.7	CHINA	2003-12-05	<input checked="" type="radio"/> Yes <input type="radio"/> No
Additional Foreign Priority Data may be generated within this form by selecting the Add button.			

### Assignee Information:


Providing this information in the application data sheet does not substitute for compliance with any requirement of part 3 of Title 37 of the CFR to have an assignment recorded in the Office.	
<b>Assignee 1</b>	
If the Assignee is an Organization check here. <input checked="" type="checkbox"/>	



<b>Application Data Sheet 37 CFR 1.76</b>		<b>Attorney Docket Number</b>	8378/88501
		<b>Application Number</b>	
<b>Title of Invention</b>	A Method For The Enantiomeric Separation Of Optical Active Amlodipine		

<b>Organization Name</b>	Shijiazhuang Pharmaceutical Group Ouyi Pharma. Co., Ltd.		
<b>Mailing Address Information:</b>			
<b>Address 1</b>	Zhong-shan West Road 276		
<b>Address 2</b>			
<b>City</b>	Shijiazhuang, Hebei Province	<b>State/Province</b>	
<b>Country</b>	CN	<b>Postal Code</b>	050051
<b>Phone Number</b>		<b>Fax Number</b>	
<b>Email Address</b>			
Additional Assignee Data may be generated within this form by selecting the Add button.			

### Signature:

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 10.18. Please see 37 CFR 1.4(d) for the form of the signature.			
<b>Signature</b>			<b>Date (YYYY-MM-DD)</b>
<b>First Name</b>	Edward E.	<b>Last Name</b>	Clair
		<b>Registration Number</b>	51.565

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	2037456
<b>Application Number:</b>	10596209
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3439
<b>Title of Invention:</b>	Method for the enantiomeric separation of optical active amlodipine
<b>First Named Inventor/Applicant Name:</b>	Nanping Zhong
<b>Customer Number:</b>	22242
<b>Filer:</b>	Edward E. Clair/Susan Hlebasko
<b>Filer Authorized By:</b>	Edward E. Clair
<b>Attorney Docket Number:</b>	8378/88501
<b>Receipt Date:</b>	01-AUG-2007
<b>Filing Date:</b>	02-JUN-2006
<b>Time Stamp:</b>	17:33:11
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Corrected Filing Receipt	88501_RequestForCorrected FilingReceipt_08012007.pdf	749427 <small>df51e97d0cd8116ea290280926251e770213 enc2bda</small>	no	17

**Warnings:**

**Information:****Total Files Size (in bytes):**

749427

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.